A team of scientists led by Rong Lu from USC and Akil A. Merchant from Cedars-Sinai introduced a genetic technology correlating gene expression signatures with cancer progression and chemotherapy resistance in leukemia.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
